Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Burkhard Schmidt

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|December 5, 2014
Organizational justice is related to heart rate variability in white-collar workers, but not in blue-collar workers-findings from a cross-sectional studyRaphael M Herr, Jos A Bosch, Annelies E M van Vianen, et al.
British Journal of Haematology|June 26, 2020
Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosisFiorenza Barraco, Richard Greil, Raoul Herbrecht, et al.
Leukemia & Lymphoma|August 22, 2015
Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study GroupValentin Goede, Raymonde Busch, Jasmin Bahlo, et al.
Annals of Hematology|January 31, 2025
How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024Martin Griesshammer, Haifa Kathrin Al-Ali, Jan-Niklas Eckardt, et al.
Haematologica|June 29, 2014
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemiaCatharina Müller-Thomas, Martina Rudelius, Ina-Christine Rondak, et al.
Atherosclerosis|September 26, 2017
Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) studyNina Schmidt, Burkhard Schmidt, Alexander Dressel, et al.
Oncotarget|May 1, 2018
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profileVeronika Reidel, Johanna Kauschinger, Richard T Hauch, et al.
Experimental Hematology & Oncology|April 25, 2019
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored doseStefanie Jilg, Richard T Hauch, Johanna Kauschinger, et al.
Blood Advances|December 1, 2022
Elevated RIPK3 correlates with disease burden in myelofibrosisVeronika Dill, Celina V Wagner, Eva C Keller, et al.
British Journal of Haematology|May 11, 2022
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysisJesko Momotow, Ina Bühnen, Karolin Trautmann-Grill, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|December 5, 2014
Organizational justice is related to heart rate variability in white-collar workers, but not in blue-collar workers-findings from a cross-sectional studyRaphael M Herr, Jos A Bosch, Annelies E M van Vianen, et al.
British Journal of Haematology|June 26, 2020
Real-world non-interventional long-term post-authorisation safety study of ruxolitinib in myelofibrosisFiorenza Barraco, Richard Greil, Raoul Herbrecht, et al.
Leukemia & Lymphoma|August 22, 2015
Low-dose fludarabine with or without darbepoetin alfa in patients with chronic lymphocytic leukemia and comorbidity: primary results of the CLL9 trial of the German CLL Study GroupValentin Goede, Raymonde Busch, Jasmin Bahlo, et al.
Annals of Hematology|January 31, 2025
How I diagnose and treat patients in the pre-fibrotic phase of primary myelofibrosis (pre-PMF) - practical approaches of a German expert panel discussion in 2024Martin Griesshammer, Haifa Kathrin Al-Ali, Jan-Niklas Eckardt, et al.
Haematologica|June 29, 2014
Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemiaCatharina Müller-Thomas, Martina Rudelius, Ina-Christine Rondak, et al.
Atherosclerosis|September 26, 2017
Familial hypercholesterolemia in primary care in Germany. Diabetes and cardiovascular risk evaluation: Targets and Essential Data for Commitment of Treatment (DETECT) studyNina Schmidt, Burkhard Schmidt, Alexander Dressel, et al.
Oncotarget|May 1, 2018
Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profileVeronika Reidel, Johanna Kauschinger, Richard T Hauch, et al.
Experimental Hematology & Oncology|April 25, 2019
Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored doseStefanie Jilg, Richard T Hauch, Johanna Kauschinger, et al.
Blood Advances|December 1, 2022
Elevated RIPK3 correlates with disease burden in myelofibrosisVeronika Dill, Celina V Wagner, Eva C Keller, et al.
British Journal of Haematology|May 11, 2022
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysisJesko Momotow, Ina Bühnen, Karolin Trautmann-Grill, et al.
Pageof 12